13 January 2010 - US medical technology company CareFusion Corporation (NYSE: CFN) said on Monday that the US Food and Drug Administration (FDA) has granted the company permission to resume manufacturing and marketing of the Alaris SE line of infusion pumps (Signature Edition infusion pump).

CareFusion, formerly the Clinical and Medical Products division of Cardinal Health, has been operating under a consent decree with the FDA since February 2007. The consent decree included an injunction on the manufacture and sale of the Alaris SE pump.

The agency recently notified CareFusion that the injunction has been lifted, allowing the company to resume sales of the Alaris SE pump.

((Comments on this story may be sent to tww.feedback@m2.com))